Biotech stocks to buy aren’t exactly the most popular investments on Wall Street right now. The “risk on” environment of 2013 seems to have evaporated, with volatility heating up and many investors taking shelter in old stalwarts like consumer staples and even bond funds. Biotech stocks are often seen as risky and more speculative by investors, particularly those who prefer entrenched health care stocks like … Continue reading Biotech Stock News: The Best Biotech Stocks In The Market Right Now

Tax inversion deals are no longer looking so attractive given the notice issued by the U.S. Department of Treasury in September. In fact, AbbVie (ABBV) has dropped its plans to acquire Shire and will be paying a break-up fee. Meanwhile, Amgen (AMGN) is being urged to consider splitting into two companies which would create more value. AbbVie called off its plans to acquire Shire – … Continue reading Biotech Stock News: A Look At The Best Prospects For The Week

Pharmacyclics (PCYC) announced that it has teamed up with Roche (RHHBY) for evaluating the safety, tolerability and preliminary efficacy of its oncology treatment, Imbruvica, in combination with the latter’s Gazyva. The companies will assess the cocktail therapy in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in multiple clinical trials. As per the deal, the combination will initially be evaluated in … Continue reading Biotech Stocks Making Headlines: Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy

Amgen Inc (AMGN) has filed a lawsuit against Sanofi (SNY ) and Regeneron Pharmaceuticals, Inc. (REGN) in the U.S. District Court of Delaware. The lawsuit is related to the infringement of certain patents (patent numbers 8,563,698, 8,829,165, and 8,859,741) owned by Amgen which describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). Sanofi and Regeneron are jointly developing alirocumab (proposed trade name: … Continue reading Biotech Stock News: Amgen Sues Sanofi and Regeneron

AbbVie Inc (ABBV) has announced that it jointly agreed with Shire plc (SHPG) to terminate the planned acquisition of the latter, which was due to be completed by year end. We remind investors that in Jul 2014, AbbVie had agreed to acquire Shire for approximately £53.19 per Shire share (£24.44 in cash and 0.8960 ordinary shares of the merged company for each Shire share). The … Continue reading Major Biotech Stock News: AbbVie Drops Shire Deal

Prosensa Holding N.V. (RNA) announced that it has initiated the process of rolling submission of a new drug application (NDA) to the FDA for its lead candidate, drisapersen, for the treatment of Duchenne muscular dystrophy (DMD). Drisapersen has Breakthrough Therapy Designation in the U.S. Moreover, the fast track status for drisapersen has made Prosensa eligible for making a rolling NDA submission for the candidate. According … Continue reading Biotech Stock News: Prosensa Starts Rolling NDA Submission, Stock Reacts